Finn
IMVT Biotechnology · Clinical stage · Autoimmune · Pre revenue · Thesis updated November 15, 2026

One drug carries the whole story as options narrow

01 Running thesis

A cleaner but riskier bet

Immunovant used to have two active drugs in the story. That changed in April 2026 when batoclimab failed two Phase 3 studies in thyroid eye disease. The company stopped all batoclimab development as a result. Now, the pipeline is narrowing further. Management announced in November 2026 that IMVT-1402 failed its trial in cutaneous lupus and that the company will likely drop its Sjögren's disease program.

The bull case relies entirely on IMVT-1402 succeeding in its remaining targets. This drug is designed to lower harmful IgG antibodies with less effect on albumin and LDL cholesterol. In late 2026, the drug showed strong response rates in a rheumatoid arthritis trial. A 600mg dose maintained a response for 92.5 percent of patients compared to about 75 percent for placebo. This gave the company strong proof that IMVT-1402 works in patients who need deep antibody suppression.

The bear case is simple. One drug carries all of the company value, and the list of diseases it can treat is getting shorter. A clinical delay, safety problem, or regulatory rejection would hurt the whole thesis at once.

The balance sheet gives the company room to try. Management has stated that existing cash can fund announced programs through a possible first commercial launch of IMVT-1402 in Graves' Disease. That lowers near-term financing risk, but clinical risk remains high.

Nov 2026→IMVT-1402 successfully hit its primary endpoint in Period 2 of the D2T RA trial. However, the pipeline was narrowed as the CLE study failed and the Sjögren's disease program will likely not progress.
Aug 2026→Management maintained focus on upcoming IMVT-1402 readouts for CLE and D2T RA in the second half of 2026, and reiterated confidence in the asset's potential in Graves' disease.
May 2026▼Immunovant stopped all batoclimab development after two Phase 3 thyroid eye disease studies failed. The story became clearer, but more dependent on one asset, IMVT-1402.
Feb 2026→The company pushed D2T RA data to the second half of calendar 2026 and set CIDP and Sjögren's disease data for 2028. Cash guidance improved to fund through a possible first IMVT-1402 launch in Graves' Disease.
Nov 2025▼Batoclimab thyroid eye disease data were delayed so both Phase 3 studies could read out together in the first half of calendar 2026. Strong Graves' Disease follow-up data helped, but the near-term catalyst moved later.
Aug 2025▲Immunovant had started studies in all six initial IMVT-1402 indications. The same filing added early warning of possible disagreement with HanAll over batoclimab.
May 2025▲The company had initiated five IMVT-1402 trials, including potentially registrational studies in MG and CIDP. Management also said $714.0 million of cash could fund operations through the Graves' Disease readout expected in 2027.
Feb 2025▲A $450.0 million private placement strengthened the balance sheet. Immunovant also had six active INDs for IMVT-1402 and had started potentially registrational trials in Graves' Disease and D2T RA.
02 Business model

No sales until approval

Immunovant is a pre-revenue biotech. It does not sell any medicine today. Its value depends on running clinical trials, getting regulators to approve IMVT-1402, and then selling or partnering the drug.

The company funds itself through stock offerings instead of product cash flow. That is common for clinical-stage biotech, but it means shareholders face dilution if trials take longer or cost more than planned.

The possible moat is the drug profile and the patents around it. IMVT-1402 is given under the skin and targets FcRn, a receptor that helps IgG antibodies stay in the body. Blocking FcRn can lower IgG, which may help diseases where IgG antibodies attack healthy tissue.

The model breaks easily. If IMVT-1402 cannot show strong benefit and clean safety in late-stage trials, there is no second active drug program to rely on.

03 Product portfolio

IMVT-1402 takes center stage

Growth engine

IMVT-1402 in Graves' Disease

This is the lead commercial target. Immunovant expects top-line results from the IMVT-1402 Graves' Disease trials in 2027.

Growth engine

IMVT-1402 in difficult-to-treat rheumatoid arthritis

This program showed positive Phase 2 maintenance data in late 2026. The company expects FDA feedback on a Phase 3 trial design soon.

Option

IMVT-1402 in myasthenia gravis

Myasthenia gravis is already a proven anti-FcRn market for other companies. Immunovant expects IMVT-1402 top-line results in MG in 2027.

Option

IMVT-1402 in chronic inflammatory demyelinating polyneuropathy

CIDP is a nerve disease where lowering harmful antibodies may help. Immunovant expects top-line results from this trial in 2028.

Steady

IMVT-1402 in Sjögren's disease

Management stated in November 2026 that the company will likely not progress this program based on updates in the field.

Steady

IMVT-1402 in cutaneous lupus erythematosus

This proof-of-concept trial failed in 2026 and did not succeed in showing the needed benefit.

Steady

Batoclimab

Batoclimab is no longer an active development program. Immunovant stopped all work on it after two Phase 3 thyroid eye disease studies missed their primary goals.

04 Business segments

One research company

Research and development100%growing fast
Commercial products0%flat

For fiscal 2026, Immunovant did not report revenue segments because it had no commercial products and had not generated revenue to date. The practical mix is all research and development activity.

05 Risk factors

What could break the thesis

Single-asset dependence

High impact · Medium odds

Immunovant is tied entirely to IMVT-1402. That focus can help execution, but it also means a bad safety signal or weak efficacy result would damage the whole company. Recent failures in lupus and Sjögren's show the drug will not work everywhere.

We watchAny IMVT-1402 trial halt, safety update, or missed primary endpoint.

HanAll partnership dispute

Medium impact · Medium odds

Immunovant licenses key assets from HanAll. Following the stop of batoclimab, HanAll may disagree with Immunovant's actions. The matter could lead to arbitration or litigation, creating cost, delay, or distraction.

We watchSEC filings or company updates that mention HanAll arbitration, litigation, settlement terms, or changes to licensed rights.

Manufacturing and BIOSECURE Act risk

Medium impact · Medium odds

The BIOSECURE Act could restrict the use of some foreign contract manufacturers if they are named as biotechnology companies of concern. If any Immunovant supplier is affected, the company may need to move manufacturing, which is costly and slow.

We watchCompany disclosure on affected CMOs, manufacturing transfers, new supply agreements, or added launch costs.

FcRn competition

High impact · High odds

The anti-FcRn field is crowded. Immunovant faces competitors like argenx, which has established strong class leadership in MG and CIDP. IMVT-1402 must show enough safety, efficacy, or convenience to win market share.

We watchNew FcRn approvals, label expansions, pricing changes, and head-to-head or cross-trial safety comparisons.

Future dilution

Medium impact · Low odds

Management says current cash can fund announced programs through a possible first IMVT-1402 launch in Graves' Disease. Still, delays, extra trials, litigation, or manufacturing changes could force another equity raise.

We watchQuarterly cash balance, operating cash burn, and any new stock offering.
06 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 15, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Immunovant Q2 FY2027 Earnings Transcript, November 9, 2026
  2. Immunovant Q1 FY2027 Earnings Transcript, August 6, 2026
  3. Immunovant FY2026 Form 10-K, filed May 20, 2026
07 Explore the industry

Comparable Biotechnology companies

Companies near Immunovant, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today